Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) Receives Consensus Rating of “Hold” by Brokerages

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN- Get a rating) received an average recommendation of “Hold” by the nine analysts who currently cover the company, reports Marketbeat Ratings. Five investment analysts rated the stock with a hold recommendation and two gave the company a buy recommendation. The 12-month average price target among analysts who have rated the stock over the past year is $153.93.

Several analysts have recently commented on BHVN’s actions. SVB Leerink downgraded shares of Biohaven Pharmaceutical from an “outperform” rating to a “market performer” rating and set a price target of $150.00 for the stock. in a Wednesday, May 11 research report. Piper Sandler lowered her price target on Biohaven Pharmaceutical shares from $156.00 to $149.00 and gave the stock an “na” rating in a Tuesday, May 24 research report. HC Wainwright downgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating in a Wednesday, May 11 research report. Wedbush downgraded shares of Biohaven Pharmaceutical from an “outperform” rating to a “neutral” rating and set a price target of $148.50 for the stock. in a research report on Monday, August 8. Finally, Cantor Fitzgerald downgraded shares of Biohaven Pharmaceutical from an “overweight” rating to a “neutral” rating in a Wednesday, May 11 research report.

Biohaven Pharmaceutical Price Performance

NYSE: BHVN opened at $147.76 on Monday. The company has a market capitalization of $10.56 billion, a P/E ratio of -9.97 and a beta of 1.03. Biohaven Pharmaceutical has a 1-year low of $79.01 and a 1-year high of $151.51. The company’s fifty-day moving average price is $145.55 and its 200-day moving average price is $131.14.

Hedge funds weigh on Biohaven Pharmaceutical

Several hedge funds and other institutional investors have recently increased or reduced their stakes in the stock. Ramius Advisors LLC bought a new position in Biohaven Pharmaceutical during the second quarter worth $3,045,000. Virtu Financial LLC bought a new position in shares of Biohaven Pharmaceutical in the second quarter worth approximately $207,000. Gamco Investors INC. ET AL bought a new position in shares of Biohaven Pharmaceutical in the second quarter worth approximately $2,945,000. Renaissance Technologies LLC purchased a new stock position in Biohaven Pharmaceutical in the second quarter worth approximately $10,258,000. Finally, Vanguard Custom Indexing Management LLC increased its stake in shares of Biohaven Pharmaceutical by 87.2% in the second quarter. Vanguard Custom Indexing Management LLC now owns 6,327 shares of the company worth $922,000 after purchasing 2,947 additional shares in the last quarter. 88.03% of the shares are held by hedge funds and other institutional investors.

About Biohaven Pharmaceutical

(Get a rating)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, is developing product candidates targeting neurological and neuropsychiatric diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as the development of Rimegepant for the preventive treatment of migraine; Zavegepant which is in Phase III clinical trials for the acute and preventive treatment of migraine, as well as for respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

See also

Analyst Recommendations for Biohaven Pharmaceutical (NYSE: BHVN)

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Biohaven Pharmaceutical, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Biohaven Pharmaceutical wasn’t on the list.

While Biohaven Pharmaceutical currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here